Sildenafil
TabletSexual Health
InjectionSexual HealthIn stock
PT-141 injection
A desire-pathway option for sexual-health programs that want to go beyond ED tablets. PT-141 works centrally rather than on blood flow, and it serves both men and women, so it widens the audience of a program already built on cash-pay checkout, provider review, and refill logic.
Starting dose
1.75 mg PRN
Patient fit
Men & women
Format
Subcutaneous injection, as needed
Pathway
Central melanocortin, not vascular
Rx required
Yes, licensed provider review
Audience
Men and women, off-label for most use
About the medication
A desire-pathway add that complements your ED options
PT-141 (bremelanotide) is a melanocortin receptor agonist that acts on central nervous system pathways tied to sexual desire and arousal, rather than the vascular mechanism PDE5 inhibitors use. The brand product Vyleesi was FDA-approved in 2019 for premenopausal women with acquired, generalized hypoactive sexual desire disorder; use in men and in postmenopausal women is off-label and is typically accessed through 503A or 503B compounding. The Vyleesi label directs patients to dose at least 45 minutes before anticipated sexual activity, with no more than one dose in 24 hours and no more than eight per month.
- Targets desire and arousal centrally, which is a different complaint than the erection-focused PDE5 class
- One of the few sexual-health molecules with a meaningful female patient base, which expands the program's reach
- Pairs cleanly with sildenafil, tadalafil, or vardenafil for patients whose issue is desire rather than blood flow
- Needs blood-pressure and cardiovascular screening, plus clear nausea counseling, built into intake and provider review
Mechanism
Melanocortin receptor agonist acting on central desire and arousal pathways.
Delivery
Subcutaneous injection taken as needed ahead of activity, not on a daily schedule.
Audience
Used by both men and women, which is unusual for a sexual-health SKU.
Oversight
Provider review covers blood pressure, cardiovascular history, and nausea expectations.
What Actually Changes The Experience
PT-141 changes the mechanism, not just the molecule
The charts use the same label-based lead time and half-life lens as the PDE5 options so you can position the planning rhythm. The real difference is upstream: PT-141 works on the central desire pathway, so it fits patients the vascular options do not fully address.
How much planning ahead is typical
Lower lead time means a smaller wait before sexual activity.
Current pageOther options
How long the molecule stays around
Longer terminal half-life usually creates a longer planning and refill story.
Current pageOther options
Best fit
Desire, not just erections
PT-141 is strongest when the patient complaint is low desire or arousal rather than the ability to get an erection.
Why teams add it
Different pathway
It lets a program help PDE5 non-responders and reach women, instead of offering three versions of the same vascular mechanism.
Screening focus
Blood pressure & nausea
Transient blood-pressure increases and nausea are the label issues to encode into intake and counseling.
Lead time uses label instructions for when patients are told to dose before sex.
Half-life uses published prescribing-information pharmacokinetics.
Comparison uses U.S. prescribing-information lead-time instructions and terminal half-life data to help with program positioning. It is not a head-to-head efficacy or safety ranking.
Program Guidance
What the team needs to get right before launch
PT-141 is an as-needed injection, so the workflow is closer to a PRN ED offer than a daily membership. The added work is screening cardiovascular risk and setting honest expectations about nausea and onset.
Starting dose
1.75 mg as needed
The Vyleesi label uses a 1.75 mg subcutaneous dose; compounded protocols vary, so provider direction matters.
When to take
≥ 45 minutes before
Patients dose ahead of anticipated activity rather than reacting in the moment.
Frequency
Max 1 per 24 hours
The label also caps use at no more than eight doses per month.
Key caveat
Cardiovascular screening
Avoid use with uncontrolled hypertension or known cardiovascular disease, and counsel on common nausea.
This page summarizes brand-label use patterns for bremelanotide and common compounded positioning. It does not replace patient-specific medical screening, and off-label use should be a documented provider decision.
The Turbopills stack for this program
Everything you need to run a PT-141 program
Launch the landing page, intake, provider routing, refill logic, and billing flow for a desire-focused cash-pay offer that sits alongside your existing ED options without stitching together separate vendors.
Product website & ad landing pages
Turbopills AI Studio — ad images & videos
BetaProvider review & e-Rx
Pharmacy order routing
Refills & auto-ship
Experiments & A/B tests
BetaReady to launch
Add the desire pathway to your sexual-health lineup.
The platform ships the intake, medical-review workflow, cardiovascular screening rules, order routing, billing, and refill logic so a PT-141 offer feels simple on the front end and stays controlled on the back end. Plug in your licensed providers and pharmacy partners, and your team focuses on positioning.
Marketing and educational content only. Clinical details on this page are summarized from publicly available sources to help operators scope a program — they are not medical advice, dosing instructions, or a recommendation for any individual patient. Real patient care requires a licensed provider and a compliant pharmacy partner; Turbopills provides the software that helps brands run the program around them.
Related
